# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001104659-23-023824
**Filing Date:** 2023-2
**Character Count:** 2476
**Document Hash:** 87963f72f431ac6aaa3556c0c2d94241
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-023824.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001104659-23-023824

**CONFORMED SUBMISSION TYPE**: IRANNOTICE

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** IRANNOTICE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 23649018

**BUSINESS ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

T: +44 (0) 20 3749 5000

astrazeneca.com

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

February 21, 2023

**Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act**

Ladies and Gentlemen,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that AstraZeneca PLC has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on February 21, 2023. The disclosure can be found under the heading "Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012" in the Annual Report on Form 20-F.

Respectfully submitted,

---

| |
|:---|
| /s/ Adrian Kemp |
| **Adrian Kemp** |
| Company Secretary |
| AstraZeneca PLC |

---

AstraZeneca PLC

Registered in England No. 2723534

Registered office: 1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom